Clinical AI and Health Tech Series - Inside the FDA's Emerging Framework for Generative AI-Enabled Medical Devices

On August 18, 2026, the U.S. Food and Drug Administration (FDA) offered new insight into how it may approach the regulation of generative AI-enabled medical devices: a two-axis risk framework and a competency-based evaluation model spanning benchmarking, clinical confirmation, and post market monitoring. As we detailed in our recent client alert, the agency is seeking comments through October 19, 2026, a narrow window to shape policy while the framework is still taking form.

Join Wilson Sonsini partners Jodi Daniel and Eva Yin, and Of Counsel Ty Kayam, who previously served as the first attorney in the FDA's Digital Health Center of Excellence, for a focused session on what the discussion paper means for developers, sponsors, and platform providers; the open questions the FDA is asking stakeholders to answer; and how to submit an effective comment before the deadline.

Seminar Information
Seminar Date:
September 29, 2026
Inside the FDA's Emerging Framework for Generative AI-Enabled Medical Devices
Speaker Information
Jodi Daniel  [ view bio ]
Ty Kayam  [ view bio ]
Eva Yin  [ view bio ]
Individual topic purchase: Selected
California
General Credits: 0.50
California Paralegal
General Credits: 0.50
New York
Professional Practice Credits: 0.50
Texas
General Credits: 0.50
Products
Streaming + MP4 Download
This Seminar is presented free of charge.